Plain-English translation of NCT07215520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new COVID-19 vaccine called that is given as a nasal spray instead of an injection. Researchers want to see if this medication is safe, works well, and causes fewer or milder side effects than the standard COVID-19 booster vaccine that you get as a shot in your arm. About 200 people who have already received COVID-19 vaccines will participate.
Scientists are looking for better ways to protect against COVID-19, especially for people at higher risk of serious illness. This medication was designed to be easier to give (nasal spray instead of injection) and might provide stronger protection by working at the site where COVID-19 viruses first enter the body.
You will be randomly assigned to receive either the new nasal vaccine plus a placebo shot, or a placebo nasal spray plus the standard COVID-19 booster shot. Neither you nor the study team will know which group you're in. You will need to attend study visits to receive your dose(s) and have your health monitored for side effects and safety over a defined period of time. The study team will check in with you to track how you feel and gather information about your health.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
CastleVax Inc.
Enrollment target
~200 participants
Started
November 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.